Phase II Study of Cabozantinib in Patients With Gastrointestinal Stromal Tumor (GIST) Who Progressed During Neoadjuvant, Adjuvant or Palliative Therapy With Imatinib and Sunitinib
Status: Active, no longer recruiting
Phase of Trial: Phase II
Latest Information Update: 20 Nov 2019
Price : $35 *
At a glance
- Drugs Cabozantinib (Primary)
- Indications Gastrointestinal stromal tumours
- Focus Therapeutic Use
- Acronyms CaboGIST
- 18 Nov 2019 Planned End Date changed from 1 Aug 2019 to 15 Feb 2020.
- 18 Nov 2019 Status changed from recruiting to active, no longer recruiting.
- 04 Jun 2019 Primary endpoint (Progression Free Survival (PFS)) has been met, according to results presented at the 55th Annual Meeting of the American Society of Clinical Oncology.